vs
Side-by-side financial comparison of Elme Communities (ELME) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $62.1M, roughly 1.1× Elme Communities). Viridian Therapeutics, Inc.\DE runs the higher net margin — -49.0% vs -198.9%, a 149.9% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 1.7%). Elme Communities produced more free cash flow last quarter ($7.2M vs $-84.7M).
Elme Communities is a publicly traded U.S. real estate investment trust that primarily owns, operates and develops high-quality multifamily residential communities. It focuses on key growth markets across the U.S. Mid-Atlantic and Southeast, offering affordable to mid-tier housing options for diverse renter groups.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
ELME vs VRDN — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $70.6M |
| Net Profit | $-123.5M | $-34.6M |
| Gross Margin | 61.1% | — |
| Operating Margin | -183.3% | -56.7% |
| Net Margin | -198.9% | -49.0% |
| Revenue YoY | 1.7% | 81958.1% |
| Net Profit YoY | -4058.7% | 54.9% |
| EPS (diluted) | $-1.40 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $62.1M | $70.6M | ||
| Q2 25 | $62.1M | — | ||
| Q1 25 | $61.5M | — | ||
| Q4 24 | $61.3M | — | ||
| Q3 24 | $61.1M | — | ||
| Q2 24 | $60.1M | — | ||
| Q1 24 | $59.5M | — | ||
| Q4 23 | $58.9M | — |
| Q3 25 | $-123.5M | $-34.6M | ||
| Q2 25 | $-3.6M | — | ||
| Q1 25 | $-4.7M | — | ||
| Q4 24 | $-3.0M | — | ||
| Q3 24 | $-3.0M | — | ||
| Q2 24 | $-3.5M | — | ||
| Q1 24 | $-3.6M | — | ||
| Q4 23 | $-3.1M | — |
| Q3 25 | 61.1% | — | ||
| Q2 25 | 63.5% | — | ||
| Q1 25 | 64.2% | — | ||
| Q4 24 | 62.9% | — | ||
| Q3 24 | 63.5% | — | ||
| Q2 24 | 63.4% | — | ||
| Q1 24 | 63.5% | — | ||
| Q4 23 | 65.6% | — |
| Q3 25 | -183.3% | -56.7% | ||
| Q2 25 | 9.6% | — | ||
| Q1 25 | 7.8% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 11.0% | — | ||
| Q2 24 | 9.8% | — | ||
| Q1 24 | 7.5% | — | ||
| Q4 23 | 10.7% | — |
| Q3 25 | -198.9% | -49.0% | ||
| Q2 25 | -5.7% | — | ||
| Q1 25 | -7.6% | — | ||
| Q4 24 | -4.9% | — | ||
| Q3 24 | -4.9% | — | ||
| Q2 24 | -5.8% | — | ||
| Q1 24 | -6.1% | — | ||
| Q4 23 | -5.3% | — |
| Q3 25 | $-1.40 | — | ||
| Q2 25 | $-0.04 | — | ||
| Q1 25 | $-0.05 | — | ||
| Q4 24 | $-0.04 | — | ||
| Q3 24 | $-0.03 | — | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | $-0.04 | — | ||
| Q4 23 | $-0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.1M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $908.9M | $503.0M |
| Total Assets | $1.7B | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $7.1M | $490.9M | ||
| Q2 25 | $4.8M | — | ||
| Q1 25 | $6.4M | — | ||
| Q4 24 | $6.1M | — | ||
| Q3 24 | $4.8M | — | ||
| Q2 24 | $5.6M | — | ||
| Q1 24 | $4.2M | — | ||
| Q4 23 | $6.0M | — |
| Q3 25 | $908.9M | $503.0M | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — | ||
| Q4 23 | $1.2B | — |
| Q3 25 | $1.7B | $577.1M | ||
| Q2 25 | $1.8B | — | ||
| Q1 25 | $1.8B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $1.9B | — | ||
| Q1 24 | $1.9B | — | ||
| Q4 23 | $1.9B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.9M | $-84.6M |
| Free Cash FlowOCF − Capex | $7.2M | $-84.7M |
| FCF MarginFCF / Revenue | 11.6% | -120.1% |
| Capex IntensityCapex / Revenue | 14.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $86.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $15.9M | $-84.6M | ||
| Q2 25 | $29.8M | — | ||
| Q1 25 | $16.2M | — | ||
| Q4 24 | $95.2M | — | ||
| Q3 24 | $20.7M | — | ||
| Q2 24 | $28.9M | — | ||
| Q1 24 | $21.2M | — | ||
| Q4 23 | $22.9M | — |
| Q3 25 | $7.2M | $-84.7M | ||
| Q2 25 | $21.1M | — | ||
| Q1 25 | $10.5M | — | ||
| Q4 24 | $47.9M | — | ||
| Q3 24 | $8.8M | — | ||
| Q2 24 | $21.0M | — | ||
| Q1 24 | $7.6M | — | ||
| Q4 23 | $6.9M | — |
| Q3 25 | 11.6% | -120.1% | ||
| Q2 25 | 34.1% | — | ||
| Q1 25 | 17.1% | — | ||
| Q4 24 | 78.1% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 34.9% | — | ||
| Q1 24 | 12.8% | — | ||
| Q4 23 | 11.8% | — |
| Q3 25 | 14.0% | 0.2% | ||
| Q2 25 | 14.0% | — | ||
| Q1 25 | 9.2% | — | ||
| Q4 24 | 77.4% | — | ||
| Q3 24 | 19.4% | — | ||
| Q2 24 | 13.1% | — | ||
| Q1 24 | 22.9% | — | ||
| Q4 23 | 27.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELME
| Residential Segment | $57.7M | 93% |
| Other | $4.4M | 7% |
VRDN
Segment breakdown not available.
